Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
Open Access
- 2 February 2021
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (5), 1162-1172
- https://doi.org/10.1111/dom.14324
Abstract
Aim To investigate the association between routine use of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and the severity of coronavirus disease 2019 (COVID‐19) infection in patient with type 2 diabetes in a large multicentric study. Materials and Methods This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID‐19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP‐4 inhibitors users vs. non‐users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). Results Five hundred and ninety‐six participants were under DPP‐4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non‐users of DPP‐4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW‐adjusted models showed no significant association between the use of DPP‐4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77–1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78–1.17]). Similar neutral findings were found between use of DPP‐4 inhibitors and the risk of tracheal intubation and death. Conclusions These data support the safety of DPP‐4 inhibitors for diabetes management during the COVID‐19 pandemic and they should not be discontinued.Keywords
Funding Information
- Air Liquide
- Allergan
- AstraZeneca
- LifeScan
- National Humanities Center
- Novo Nordisk
- Sanofi
- Société Francophone du Diabète
- Société Francophone du Diabète
This publication has 29 references indexed in Scilit:
- Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19Acta Diabetologica, 2020
- COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?Journal of Endocrinological Investigation, 2020
- Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic ImplicationsEndocrine Reviews, 2020
- Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirusEmerging Microbes & Infections, 2020
- Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirusVirology, 2018
- Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26Stem Cells and Development, 2016
- DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trialsDiabetes/Metabolism Research and Reviews, 2015
- Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4The Journal of Infectious Diseases, 2015
- Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infectionProceedings of the National Academy of Sciences, 2015
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 InhibitorsEndocrine Reviews, 2014